MedPath

The Effect of Dexmedetomidine During Opioid Free Anesthesia on Postoperative Recovery After Gastrectomy

Not Applicable
Completed
Conditions
Gastric Cancer
Interventions
Registration Number
NCT04529135
Lead Sponsor
Gangnam Severance Hospital
Brief Summary

"Want to know the effect of dexmedetomidine during opioid free anesthesia on postoperative recovery after gastrectomy. Patients undergoing open gastrectomy are divided into dexmedetomidine group and control(remifentanil) group, administered during surgery, and compared with the speed of postoperative intestinal function recovery. Based on our institution's previous record, the average recovery time was 6 ± 1.4 days. Given that it is clinically significant to reduce recovery time by 20%, Alpha 0.05 and Power 80% require 31 samples per group, and assuming a 10% dropout rate, the total number of samples needed is 68.Subjects are patients aged 19 to 75 who are subject to open gastretomy planned by a gastric cancer. The exclusion criteria include American Society of Anesthesiology grade 3 or higher, patients who have previously been treated for cancer, patients with cancer other than the stomach, patients with drug allergies, weight less than 60kg, BMI \> 30 kg/m2, patients who are unable to communicate and are unable to read consent (e.g., illiteracy, foreigners, etc.). The research method is a Randomized double-blind controlled study, and the assignment of both drugs is unknown and is used to maintain anesthesia in the form of continuous injection during surgery. Primary outcome is the recovery period satisfying the following. 1)intestinal gas passage 2) tolerance of soft bland diet (SBD) for 24 hr. 3) safe ambulation without assistance 4) no requirement iv analgesics after discontinuation of PCA (VAS \<4). 5) no abnormal physical signs or laboratory test. The secondary outcomes are maximum VAS, post-operative hospital stay, complications and readmission rate at 3 months F/U time, post-operative period analgesic requirement, incidence of opioid related side effect.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
68
Inclusion Criteria

-patients undergoing open gastrectomy for gastric cancer

Exclusion Criteria
  • American Society of Anesthesiology grade 3 or higher
  • history of chemotherapy
  • diagosis of cancer in other organs
  • history of drug allergy
  • weight less than 60kg
  • BMI over 30 kg/m2 patient
  • cognitive impairment
  • gait disturbance

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DexmedetomidineDexmedetomidineIV,0.2\~0.8 µg/kg/hr
RemifentanilRemifentanilIV,0.05\~0.2 µg/kg/min
Primary Outcome Measures
NameTimeMethod
postoperative recovery time3 months

number of days satisfying all following criteria 1)intestinal gas passage 2) tolerance of soft bland diet (SBD) for 24 hr. 3) safe ambulation without assistance 4) no requirement iv analgesics after discontinuation of PCA (VAS \<4). 5) no abnormal physical signs or laboratory test.

Secondary Outcome Measures
NameTimeMethod
complications and readmission rate at 3 months F/U time3 months

incidence

maximum pain score3 months

Visual analogue scale (VAS: 0-10)

post-operative hospital stay3 months

days

post-operative period analgesic requirement3 months

number of analgesic requirement despite intravenous patient controlled analgesia

opioid related side effect.3 months

incidence of nausea, vomiting and pruritus

Trial Locations

Locations (1)

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath